Loading…
SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)
From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that wer...
Saved in:
Published in: | Japanese journal of antibiotics 2004/06/25, Vol.57(3), pp.213-245 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | Japanese |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 245 |
container_issue | 3 |
container_start_page | 213 |
container_title | Japanese journal of antibiotics |
container_volume | 57 |
creator | SHIMADA, KAORU NAKANO, KUNIO IGARI, JUN OGURI, TOYOKO IDEMOTO, HIDEO MORI, TAKESHI YOKOUCHI, HIROSHI YAMAMOTO, MAKOTO INOUE, HIROSHI NAKADATE, TOSHIHIDE SUWABE, AKIRA OKADA, SHINJI ASHINO, YUGO GEJYO, FUMITAKE OKADA, MASAHIKO AOKI, NOBUKI KITAMURA, NOBUKO SUZUKI, YASUTOSHI KARASAWA, YASUO NADATA, KOICHIRO NADATANI, TATSUO INAGAWA, HIROKO KUDO, KOUICHIRO KOBAYASHI, NOBUYUKI TANAKA, TSUKASA KOBAYASHI, HIROYUKI GOTO, HAJIME KAWAI, SHIN TAKEDA, HIDENORI SUMITOMO, MIDORI MATSUSHIMA, TOSHIHARU NIKI, YOSHIHITO KOHNO, SHIGERU MIYAZAKI, YOSHITUGU YANAGIHARA, KATSUNORI HIRAKATA, YOICHI MATSUDA, JUNICHI NASU, MASARU HIRAMATSU, KAZUFUMI SUGA, MORITAKA TOSAKA, MASAKAZU |
description | From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents gen |
doi_str_mv | 10.11553/antibiotics1968b.57.213 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66891007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66891007</sourcerecordid><originalsourceid>FETCH-LOGICAL-j218t-7dde83f58e7ad4692aa15a15a744242d4ed7f94009dc1c0c95a4f9eea763c9043</originalsourceid><addsrcrecordid>eNpdkUtP4zAURq3RoKEC_sLIqxGzSPEzdpYhuINRpq5iV2hWkZu4ENQHxOli_j2peCyQrr67OTrSvR8AEKMpxpzTK78bulW3H7om4iyVqykXU4LpNzAhWKYJZ0J8BxNEU5kQIfEpuIixWyGKhSSj4Qc4xZyKVEg2AdEubaEWTl_rUjutLDQzeJ0XTlU6h9qaMnfqBs4q8xcu8hGYOwvvtbuFpblXFayUXegqd6b6B_V8pgqnzdLCG21VbkebMzCfH-3G6cJeEoTI73NwsvabGC7e9xlYzpQrbpPS_NFFXiZP4x1DIto2SLrmMgjfsjQj3mN-HMEYYaRloRXrjCGUtQ1uUJNxz9ZZCF6ktMkQo2fg15v3ud-_HEIc6m0Xm7DZ-F3YH2KdpjLDCIkR_PkOHlbb0NbPfbf1_f_6400jcPcGPMXBP4RPwPdjCZtQf22k5qKmxxhr-YSaR9_XYUdfAXSqgB8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66891007</pqid></control><display><type>article</type><title>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</title><source>Alma/SFX Local Collection</source><creator>SHIMADA, KAORU ; NAKANO, KUNIO ; IGARI, JUN ; OGURI, TOYOKO ; IDEMOTO, HIDEO ; MORI, TAKESHI ; YOKOUCHI, HIROSHI ; YAMAMOTO, MAKOTO ; INOUE, HIROSHI ; NAKADATE, TOSHIHIDE ; SUWABE, AKIRA ; OKADA, SHINJI ; ASHINO, YUGO ; GEJYO, FUMITAKE ; OKADA, MASAHIKO ; AOKI, NOBUKI ; KITAMURA, NOBUKO ; SUZUKI, YASUTOSHI ; KARASAWA, YASUO ; NADATA, KOICHIRO ; NADATANI, TATSUO ; INAGAWA, HIROKO ; KUDO, KOUICHIRO ; KOBAYASHI, NOBUYUKI ; TANAKA, TSUKASA ; KOBAYASHI, HIROYUKI ; GOTO, HAJIME ; KAWAI, SHIN ; TAKEDA, HIDENORI ; SUMITOMO, MIDORI ; MATSUSHIMA, TOSHIHARU ; NIKI, YOSHIHITO ; KOHNO, SHIGERU ; MIYAZAKI, YOSHITUGU ; YANAGIHARA, KATSUNORI ; HIRAKATA, YOICHI ; MATSUDA, JUNICHI ; NASU, MASARU ; HIRAMATSU, KAZUFUMI ; SUGA, MORITAKA ; TOSAKA, MASAKAZU</creator><creatorcontrib>SHIMADA, KAORU ; NAKANO, KUNIO ; IGARI, JUN ; OGURI, TOYOKO ; IDEMOTO, HIDEO ; MORI, TAKESHI ; YOKOUCHI, HIROSHI ; YAMAMOTO, MAKOTO ; INOUE, HIROSHI ; NAKADATE, TOSHIHIDE ; SUWABE, AKIRA ; OKADA, SHINJI ; ASHINO, YUGO ; GEJYO, FUMITAKE ; OKADA, MASAHIKO ; AOKI, NOBUKI ; KITAMURA, NOBUKO ; SUZUKI, YASUTOSHI ; KARASAWA, YASUO ; NADATA, KOICHIRO ; NADATANI, TATSUO ; INAGAWA, HIROKO ; KUDO, KOUICHIRO ; KOBAYASHI, NOBUYUKI ; TANAKA, TSUKASA ; KOBAYASHI, HIROYUKI ; GOTO, HAJIME ; KAWAI, SHIN ; TAKEDA, HIDENORI ; SUMITOMO, MIDORI ; MATSUSHIMA, TOSHIHARU ; NIKI, YOSHIHITO ; KOHNO, SHIGERU ; MIYAZAKI, YOSHITUGU ; YANAGIHARA, KATSUNORI ; HIRAKATA, YOICHI ; MATSUDA, JUNICHI ; NASU, MASARU ; HIRAMATSU, KAZUFUMI ; SUGA, MORITAKA ; TOSAKA, MASAKAZU</creatorcontrib><description>From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents generally showed potent activities against M.(B.) catarrhalis and the MIC90 of all drugs were 4μg/ml or less. The approximately half the number (47.5%) of the patients with respiratory infection were aged 70 years or older. As for the incidence by the diseases, bacterial pneumonia and chronic bronchitis were the highest, being noted in 35.7 and 33.8% of all the patients, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (22.6%). In contrast, S. aureus (16.6%) and P aeruginosa (13.7%) were relatively frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from all the patients were H. influenzae (24.5%) and S. pneumoniae (24.2%). In comparison of the isolated bacteria by pretreatment agents, P. aeruginosa was relatively frequently isolated from the patients pretreated with cephems or macrolides and H. influenzae was relatively frequently isolated from the patients pretreated with penicillins.</description><identifier>ISSN: 0368-2781</identifier><identifier>EISSN: 2186-5477</identifier><identifier>DOI: 10.11553/antibiotics1968b.57.213</identifier><identifier>PMID: 15376784</identifier><language>jpn</language><publisher>Japan: Japan Antibiotics Research Association</publisher><subject>Anti-Bacterial Agents - pharmacology ; Bacteria - drug effects ; Bacteria - isolation & purification ; Drug Resistance, Bacterial ; Humans ; Respiratory Tract Infections - microbiology ; Time Factors</subject><ispartof>The Japanese Journal of Antibiotics, 2004/06/25, Vol.57(3), pp.213-245</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15376784$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHIMADA, KAORU</creatorcontrib><creatorcontrib>NAKANO, KUNIO</creatorcontrib><creatorcontrib>IGARI, JUN</creatorcontrib><creatorcontrib>OGURI, TOYOKO</creatorcontrib><creatorcontrib>IDEMOTO, HIDEO</creatorcontrib><creatorcontrib>MORI, TAKESHI</creatorcontrib><creatorcontrib>YOKOUCHI, HIROSHI</creatorcontrib><creatorcontrib>YAMAMOTO, MAKOTO</creatorcontrib><creatorcontrib>INOUE, HIROSHI</creatorcontrib><creatorcontrib>NAKADATE, TOSHIHIDE</creatorcontrib><creatorcontrib>SUWABE, AKIRA</creatorcontrib><creatorcontrib>OKADA, SHINJI</creatorcontrib><creatorcontrib>ASHINO, YUGO</creatorcontrib><creatorcontrib>GEJYO, FUMITAKE</creatorcontrib><creatorcontrib>OKADA, MASAHIKO</creatorcontrib><creatorcontrib>AOKI, NOBUKI</creatorcontrib><creatorcontrib>KITAMURA, NOBUKO</creatorcontrib><creatorcontrib>SUZUKI, YASUTOSHI</creatorcontrib><creatorcontrib>KARASAWA, YASUO</creatorcontrib><creatorcontrib>NADATA, KOICHIRO</creatorcontrib><creatorcontrib>NADATANI, TATSUO</creatorcontrib><creatorcontrib>INAGAWA, HIROKO</creatorcontrib><creatorcontrib>KUDO, KOUICHIRO</creatorcontrib><creatorcontrib>KOBAYASHI, NOBUYUKI</creatorcontrib><creatorcontrib>TANAKA, TSUKASA</creatorcontrib><creatorcontrib>KOBAYASHI, HIROYUKI</creatorcontrib><creatorcontrib>GOTO, HAJIME</creatorcontrib><creatorcontrib>KAWAI, SHIN</creatorcontrib><creatorcontrib>TAKEDA, HIDENORI</creatorcontrib><creatorcontrib>SUMITOMO, MIDORI</creatorcontrib><creatorcontrib>MATSUSHIMA, TOSHIHARU</creatorcontrib><creatorcontrib>NIKI, YOSHIHITO</creatorcontrib><creatorcontrib>KOHNO, SHIGERU</creatorcontrib><creatorcontrib>MIYAZAKI, YOSHITUGU</creatorcontrib><creatorcontrib>YANAGIHARA, KATSUNORI</creatorcontrib><creatorcontrib>HIRAKATA, YOICHI</creatorcontrib><creatorcontrib>MATSUDA, JUNICHI</creatorcontrib><creatorcontrib>NASU, MASARU</creatorcontrib><creatorcontrib>HIRAMATSU, KAZUFUMI</creatorcontrib><creatorcontrib>SUGA, MORITAKA</creatorcontrib><creatorcontrib>TOSAKA, MASAKAZU</creatorcontrib><title>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</title><title>Japanese journal of antibiotics</title><addtitle>Jpn. J. Antibiotics</addtitle><description>From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents generally showed potent activities against M.(B.) catarrhalis and the MIC90 of all drugs were 4μg/ml or less. The approximately half the number (47.5%) of the patients with respiratory infection were aged 70 years or older. As for the incidence by the diseases, bacterial pneumonia and chronic bronchitis were the highest, being noted in 35.7 and 33.8% of all the patients, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (22.6%). In contrast, S. aureus (16.6%) and P aeruginosa (13.7%) were relatively frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from all the patients were H. influenzae (24.5%) and S. pneumoniae (24.2%). In comparison of the isolated bacteria by pretreatment agents, P. aeruginosa was relatively frequently isolated from the patients pretreated with cephems or macrolides and H. influenzae was relatively frequently isolated from the patients pretreated with penicillins.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - isolation & purification</subject><subject>Drug Resistance, Bacterial</subject><subject>Humans</subject><subject>Respiratory Tract Infections - microbiology</subject><subject>Time Factors</subject><issn>0368-2781</issn><issn>2186-5477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdkUtP4zAURq3RoKEC_sLIqxGzSPEzdpYhuINRpq5iV2hWkZu4ENQHxOli_j2peCyQrr67OTrSvR8AEKMpxpzTK78bulW3H7om4iyVqykXU4LpNzAhWKYJZ0J8BxNEU5kQIfEpuIixWyGKhSSj4Qc4xZyKVEg2AdEubaEWTl_rUjutLDQzeJ0XTlU6h9qaMnfqBs4q8xcu8hGYOwvvtbuFpblXFayUXegqd6b6B_V8pgqnzdLCG21VbkebMzCfH-3G6cJeEoTI73NwsvabGC7e9xlYzpQrbpPS_NFFXiZP4x1DIto2SLrmMgjfsjQj3mN-HMEYYaRloRXrjCGUtQ1uUJNxz9ZZCF6ktMkQo2fg15v3ud-_HEIc6m0Xm7DZ-F3YH2KdpjLDCIkR_PkOHlbb0NbPfbf1_f_6400jcPcGPMXBP4RPwPdjCZtQf22k5qKmxxhr-YSaR9_XYUdfAXSqgB8</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>SHIMADA, KAORU</creator><creator>NAKANO, KUNIO</creator><creator>IGARI, JUN</creator><creator>OGURI, TOYOKO</creator><creator>IDEMOTO, HIDEO</creator><creator>MORI, TAKESHI</creator><creator>YOKOUCHI, HIROSHI</creator><creator>YAMAMOTO, MAKOTO</creator><creator>INOUE, HIROSHI</creator><creator>NAKADATE, TOSHIHIDE</creator><creator>SUWABE, AKIRA</creator><creator>OKADA, SHINJI</creator><creator>ASHINO, YUGO</creator><creator>GEJYO, FUMITAKE</creator><creator>OKADA, MASAHIKO</creator><creator>AOKI, NOBUKI</creator><creator>KITAMURA, NOBUKO</creator><creator>SUZUKI, YASUTOSHI</creator><creator>KARASAWA, YASUO</creator><creator>NADATA, KOICHIRO</creator><creator>NADATANI, TATSUO</creator><creator>INAGAWA, HIROKO</creator><creator>KUDO, KOUICHIRO</creator><creator>KOBAYASHI, NOBUYUKI</creator><creator>TANAKA, TSUKASA</creator><creator>KOBAYASHI, HIROYUKI</creator><creator>GOTO, HAJIME</creator><creator>KAWAI, SHIN</creator><creator>TAKEDA, HIDENORI</creator><creator>SUMITOMO, MIDORI</creator><creator>MATSUSHIMA, TOSHIHARU</creator><creator>NIKI, YOSHIHITO</creator><creator>KOHNO, SHIGERU</creator><creator>MIYAZAKI, YOSHITUGU</creator><creator>YANAGIHARA, KATSUNORI</creator><creator>HIRAKATA, YOICHI</creator><creator>MATSUDA, JUNICHI</creator><creator>NASU, MASARU</creator><creator>HIRAMATSU, KAZUFUMI</creator><creator>SUGA, MORITAKA</creator><creator>TOSAKA, MASAKAZU</creator><general>Japan Antibiotics Research Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200406</creationdate><title>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</title><author>SHIMADA, KAORU ; NAKANO, KUNIO ; IGARI, JUN ; OGURI, TOYOKO ; IDEMOTO, HIDEO ; MORI, TAKESHI ; YOKOUCHI, HIROSHI ; YAMAMOTO, MAKOTO ; INOUE, HIROSHI ; NAKADATE, TOSHIHIDE ; SUWABE, AKIRA ; OKADA, SHINJI ; ASHINO, YUGO ; GEJYO, FUMITAKE ; OKADA, MASAHIKO ; AOKI, NOBUKI ; KITAMURA, NOBUKO ; SUZUKI, YASUTOSHI ; KARASAWA, YASUO ; NADATA, KOICHIRO ; NADATANI, TATSUO ; INAGAWA, HIROKO ; KUDO, KOUICHIRO ; KOBAYASHI, NOBUYUKI ; TANAKA, TSUKASA ; KOBAYASHI, HIROYUKI ; GOTO, HAJIME ; KAWAI, SHIN ; TAKEDA, HIDENORI ; SUMITOMO, MIDORI ; MATSUSHIMA, TOSHIHARU ; NIKI, YOSHIHITO ; KOHNO, SHIGERU ; MIYAZAKI, YOSHITUGU ; YANAGIHARA, KATSUNORI ; HIRAKATA, YOICHI ; MATSUDA, JUNICHI ; NASU, MASARU ; HIRAMATSU, KAZUFUMI ; SUGA, MORITAKA ; TOSAKA, MASAKAZU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j218t-7dde83f58e7ad4692aa15a15a744242d4ed7f94009dc1c0c95a4f9eea763c9043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2004</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - isolation & purification</topic><topic>Drug Resistance, Bacterial</topic><topic>Humans</topic><topic>Respiratory Tract Infections - microbiology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHIMADA, KAORU</creatorcontrib><creatorcontrib>NAKANO, KUNIO</creatorcontrib><creatorcontrib>IGARI, JUN</creatorcontrib><creatorcontrib>OGURI, TOYOKO</creatorcontrib><creatorcontrib>IDEMOTO, HIDEO</creatorcontrib><creatorcontrib>MORI, TAKESHI</creatorcontrib><creatorcontrib>YOKOUCHI, HIROSHI</creatorcontrib><creatorcontrib>YAMAMOTO, MAKOTO</creatorcontrib><creatorcontrib>INOUE, HIROSHI</creatorcontrib><creatorcontrib>NAKADATE, TOSHIHIDE</creatorcontrib><creatorcontrib>SUWABE, AKIRA</creatorcontrib><creatorcontrib>OKADA, SHINJI</creatorcontrib><creatorcontrib>ASHINO, YUGO</creatorcontrib><creatorcontrib>GEJYO, FUMITAKE</creatorcontrib><creatorcontrib>OKADA, MASAHIKO</creatorcontrib><creatorcontrib>AOKI, NOBUKI</creatorcontrib><creatorcontrib>KITAMURA, NOBUKO</creatorcontrib><creatorcontrib>SUZUKI, YASUTOSHI</creatorcontrib><creatorcontrib>KARASAWA, YASUO</creatorcontrib><creatorcontrib>NADATA, KOICHIRO</creatorcontrib><creatorcontrib>NADATANI, TATSUO</creatorcontrib><creatorcontrib>INAGAWA, HIROKO</creatorcontrib><creatorcontrib>KUDO, KOUICHIRO</creatorcontrib><creatorcontrib>KOBAYASHI, NOBUYUKI</creatorcontrib><creatorcontrib>TANAKA, TSUKASA</creatorcontrib><creatorcontrib>KOBAYASHI, HIROYUKI</creatorcontrib><creatorcontrib>GOTO, HAJIME</creatorcontrib><creatorcontrib>KAWAI, SHIN</creatorcontrib><creatorcontrib>TAKEDA, HIDENORI</creatorcontrib><creatorcontrib>SUMITOMO, MIDORI</creatorcontrib><creatorcontrib>MATSUSHIMA, TOSHIHARU</creatorcontrib><creatorcontrib>NIKI, YOSHIHITO</creatorcontrib><creatorcontrib>KOHNO, SHIGERU</creatorcontrib><creatorcontrib>MIYAZAKI, YOSHITUGU</creatorcontrib><creatorcontrib>YANAGIHARA, KATSUNORI</creatorcontrib><creatorcontrib>HIRAKATA, YOICHI</creatorcontrib><creatorcontrib>MATSUDA, JUNICHI</creatorcontrib><creatorcontrib>NASU, MASARU</creatorcontrib><creatorcontrib>HIRAMATSU, KAZUFUMI</creatorcontrib><creatorcontrib>SUGA, MORITAKA</creatorcontrib><creatorcontrib>TOSAKA, MASAKAZU</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHIMADA, KAORU</au><au>NAKANO, KUNIO</au><au>IGARI, JUN</au><au>OGURI, TOYOKO</au><au>IDEMOTO, HIDEO</au><au>MORI, TAKESHI</au><au>YOKOUCHI, HIROSHI</au><au>YAMAMOTO, MAKOTO</au><au>INOUE, HIROSHI</au><au>NAKADATE, TOSHIHIDE</au><au>SUWABE, AKIRA</au><au>OKADA, SHINJI</au><au>ASHINO, YUGO</au><au>GEJYO, FUMITAKE</au><au>OKADA, MASAHIKO</au><au>AOKI, NOBUKI</au><au>KITAMURA, NOBUKO</au><au>SUZUKI, YASUTOSHI</au><au>KARASAWA, YASUO</au><au>NADATA, KOICHIRO</au><au>NADATANI, TATSUO</au><au>INAGAWA, HIROKO</au><au>KUDO, KOUICHIRO</au><au>KOBAYASHI, NOBUYUKI</au><au>TANAKA, TSUKASA</au><au>KOBAYASHI, HIROYUKI</au><au>GOTO, HAJIME</au><au>KAWAI, SHIN</au><au>TAKEDA, HIDENORI</au><au>SUMITOMO, MIDORI</au><au>MATSUSHIMA, TOSHIHARU</au><au>NIKI, YOSHIHITO</au><au>KOHNO, SHIGERU</au><au>MIYAZAKI, YOSHITUGU</au><au>YANAGIHARA, KATSUNORI</au><au>HIRAKATA, YOICHI</au><au>MATSUDA, JUNICHI</au><au>NASU, MASARU</au><au>HIRAMATSU, KAZUFUMI</au><au>SUGA, MORITAKA</au><au>TOSAKA, MASAKAZU</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</atitle><jtitle>Japanese journal of antibiotics</jtitle><addtitle>Jpn. J. Antibiotics</addtitle><date>2004-06</date><risdate>2004</risdate><volume>57</volume><issue>3</issue><spage>213</spage><epage>245</epage><pages>213-245</pages><issn>0368-2781</issn><eissn>2186-5477</eissn><abstract>From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents generally showed potent activities against M.(B.) catarrhalis and the MIC90 of all drugs were 4μg/ml or less. The approximately half the number (47.5%) of the patients with respiratory infection were aged 70 years or older. As for the incidence by the diseases, bacterial pneumonia and chronic bronchitis were the highest, being noted in 35.7 and 33.8% of all the patients, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (22.6%). In contrast, S. aureus (16.6%) and P aeruginosa (13.7%) were relatively frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from all the patients were H. influenzae (24.5%) and S. pneumoniae (24.2%). In comparison of the isolated bacteria by pretreatment agents, P. aeruginosa was relatively frequently isolated from the patients pretreated with cephems or macrolides and H. influenzae was relatively frequently isolated from the patients pretreated with penicillins.</abstract><cop>Japan</cop><pub>Japan Antibiotics Research Association</pub><pmid>15376784</pmid><doi>10.11553/antibiotics1968b.57.213</doi><tpages>33</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0368-2781 |
ispartof | The Japanese Journal of Antibiotics, 2004/06/25, Vol.57(3), pp.213-245 |
issn | 0368-2781 2186-5477 |
language | jpn |
recordid | cdi_proquest_miscellaneous_66891007 |
source | Alma/SFX Local Collection |
subjects | Anti-Bacterial Agents - pharmacology Bacteria - drug effects Bacteria - isolation & purification Drug Resistance, Bacterial Humans Respiratory Tract Infections - microbiology Time Factors |
title | SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002) |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A20%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SUSCEPTIBILITIES%20OF%20BACTERIA%20ISOLATED%20FROM%20PATIENTS%20WITH%20LOWER%20RESPIRATORY%20INFECTIOUS%20DISEASES%20TO%20ANTIBIOTICS(2002)&rft.jtitle=Japanese%20journal%20of%20antibiotics&rft.au=SHIMADA,%20KAORU&rft.date=2004-06&rft.volume=57&rft.issue=3&rft.spage=213&rft.epage=245&rft.pages=213-245&rft.issn=0368-2781&rft.eissn=2186-5477&rft_id=info:doi/10.11553/antibiotics1968b.57.213&rft_dat=%3Cproquest_pubme%3E66891007%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j218t-7dde83f58e7ad4692aa15a15a744242d4ed7f94009dc1c0c95a4f9eea763c9043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66891007&rft_id=info:pmid/15376784&rfr_iscdi=true |